Nussinov, RuthWeichhart, ThomasDlamini, ZodwaGibbons, Don L.Van Seuningen, IsabelleKonen, JessicaJu, Huai-Qiang2024-12-112024-06Nussinov, R., Weichhart, T., Dlamini, Z. et al. 2024, 'Directions to overcome therapy resistance in cancer', Trends in Pharmacological Sciences, vol. 45 no. 6, pp. 467-471, doi : 10.1016/j.tips.2024.05.001.0165-6147 (print)1873-3735 (online)10.1016/j.tips.2024.05.001http://hdl.handle.net/2263/99889Novel modalities for treatment of cancer have emerged because of advances in technology that have enabled expansion of our understanding of how cells transform to become cancerous and the role of the tumor microenvironment (TME). However, resistance to therapy poses a major problem for the successful treatment of cancer. Ongoing collaborative efforts of clinicians and researchers from different parts of the world have also led to an emerging understanding of how cancer cells evolve to resist treatment. Jerry Madukwe, the Editor-in-Chief of Trends in Pharmacological Sciences asked experts in the field to reflect on the global challenges in the cancer field and provide their views on what they see as the most pressing questions and research directions to overcome therapy resistance in cancer.en© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Notice : this is the author’s version of a work that was accepted for publication in Trends in Pharmacological Sciences. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Trends in Pharmacological Sciences, vol. 45 no. 6, pp. 467-471, doi : 10.1016/j.tips.2024.05.001.Cancer treatmentTumor microenvironment (TME)Therapy resistanceSDG-03: Good health and well-beingPostprint Article